INOVIQ Ltd (ASX:IIQ)

Australia flag Australia · Delayed Price · Currency is AUD
0.330
0.00 (0.00%)
At close: Mar 6, 2026
-17.50%
Market Cap 46.46M
Revenue (ttm) 2.10M
Net Income (ttm) -7.24M
Shares Out 140.78M
EPS (ttm) -0.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,905
Average Volume 154,101
Open 0.335
Previous Close 0.330
Day's Range 0.330 - 0.335
52-Week Range 0.320 - 0.690
Beta 1.79
RSI 44.45
Earnings Date Feb 18, 2026

About INOVIQ

INOVIQ Ltd develops and commercializes diagnostic and exosome‐based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non-invasive, diagnostics using its proprietary exosome develops technologies for improved screening, diagnosis, treatment selection and monitoring of can... [Read more]

Sector Healthcare
Founded 2016
Employees 15
Stock Exchange Australian Securities Exchange
Ticker Symbol IIQ
Full Company Profile

Financial Performance

In fiscal year 2025, INOVIQ's revenue was 1.82 million, an increase of 16.25% compared to the previous year's 1.56 million. Losses were -6.93 million, 5.77% more than in 2024.

Financial Statements

News

There is no news available yet.